chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial sore arm, followed by 5-7 days (still ongoing) persistent low fever, nausea, headache, diarrhea (2 days), and significant joint pain. Occasional sore throat.; followed by 5-7 days (still ongoing) persistent low fever; Nausea; Headache; Diarrhea; Significant Joint pain; Occasional sore throat.; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the arm left on 08Apr2021 at 14:45(at the age of 63-years-old) as a single dose for COVID-19 immunisation. The medical history included lupus and allergy to gluten. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included hydroxychloroquine sulfate (PLAQUENIL), alendronate sodium (ALENDRONATE), resveratrol (MANUFACTURER UNKNOWN), glutathione (MANUFACTURER UNKNOWN) and glyc (unspecified), all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on unknown date as a single dose for COVID-19 immunisation. On 09Apr2021, the patient experienced initial sore arm which was followed by 5-7 days (ongoing at the time of report) persistent low fever, nausea, headache, diarrhea (2 days), significant joint pain and occasional sore throat. The patient did not receive any treatment for the reported events. Since the vaccination, the patient had been tested for COVID-19. On 12Apr2021, the patient underwent rapid test (SARS-CoV-2 test) and the result was negative. The clinical outcome of the event diarrhea was recovered on 11Apr2021, while the clinical outcome of the events initial sore arm, persistent low fever, nausea, headache, significant joint pain and occasional sore throat was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
WHITE BLOOD CELLS WERE ELEVATED; HIDRADENITIS SUPPURATIVA FLARE UP; This spontaneous case was reported by a consumer and describes the occurrence of WHITE BLOOD CELL COUNT INCREASED (WHITE BLOOD CELLS WERE ELEVATED) and HIDRADENITIS (HIDRADENITIS SUPPURATIVA FLARE UP) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In January 2021, the patient experienced HIDRADENITIS (HIDRADENITIS SUPPURATIVA FLARE UP). On an unknown date, the patient experienced WHITE BLOOD CELL COUNT INCREASED (WHITE BLOOD CELLS WERE ELEVATED). In January 2021, HIDRADENITIS (HIDRADENITIS SUPPURATIVA FLARE UP) had resolved. At the time of the report, WHITE BLOOD CELL COUNT INCREASED (WHITE BLOOD CELLS WERE ELEVATED) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, White blood cell count: Elevated.         It was unknown if the patient was enrolled in covid-19 vaccine trials.  No concomitant product reported by reporter.  Patient experienced hidradenitis suppurativa flare up after first covid vaccine.  No treatment medication reported by reporter.  This case was identified as part of a retrospective clean-up activity where certain emails received in the moderna mailbox were missed to be booked-in.
Patient was given a Pfizer infant Covid-19 dose instead of the Pfizer pediatric covid-19 dose.
This case was reported by a other health professional via sales rep and described the occurrence of numbness of upper extremities in a female patient who received BEXSERO for prophylaxis. Co-suspect products included HPV Vaccine solution for injection for prophylaxis. On an unknown date, the patient received BEXSERO and HPV Vaccine. On an unknown date, less than a day after receiving BEXSERO and not applicable after starting HPV Vaccine, the patient experienced numbness of upper extremities and fever. On an unknown date, the outcome of the numbness of upper extremities and fever were unknown. The reporter considered the numbness of upper extremities to be related to BEXSERO. It was unknown if the reporter considered the fever to be related to BEXSERO and HPV Vaccine. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The age at vaccination was not reported. The patient received BEXSERO and HPV shot on the same day in different arms and the patient reported high fever and arm numbness and felt that she may need to go to the emergency room. According to reporter the patient did not go to the emergency room and they had not and would not give the 2nd dose of BEXSERO. She was sure of the arm and the cause being BEXSERO.
Large swelling near injection site, redness, and hot to touch.  Started 9 days after vaccination.
Pain chest; This is a spontaneous report from a contactable consumer. This 15-year-old female contactable consumer(patient) reported that.  A 15-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), dose 2 via an unspecified route of administration, administered in Arm Left on 12Jun2021 09:00 as (At the age of 15-years) dose 2, single for covid-19 immunisation. Medical history included back pain from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. Patient was not pregnant at the time of vaccination. No other vaccine in four weeks. The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration, administered in Arm Left on 22May2021 09:00 AM as (At the age of 15-years) dose 1, single for covid-19 immunisation. It was Unknown if patient had covid prior vaccination. No covid tested post vaccination. No Known allergies ware reported. The patient experienced pain chest on 14Jun2021 08:00. Patient did not receive any treatment for events. The outcome of event was not recovered at the time of report.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected
the vaccine was extremely painful; she became nauseous; felt like she was going to pass out; This spontaneous report was received from a nurse and refers to a not-pregnant female patient of an unknown age. There was no information about the patient's concurrent conditions, concomitant therapies, drug reactions, allergies or medical history provided.  On 03-NOV-2020, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II), 0.5 milliliter, intramuscular (IM) (lot # and expiration date were not reported) for routine vaccination. She stated, that on that day, the vaccine was extremely painful, she became nauseous and felt like she was going to pass out. She did not seek medical attention an no treatment was given. On an unknown date in November 2020, the patient recovered from the events.   The causality between therapy with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) and the events of nauseous and felt like she was going to pass out was not provided. The causality between the suspect therapy and the vaccine was extremely painful was considered to be related.
Pt had chills, sweaty and a headache. She went home and went to bed and slept off and on most of the day. Symptoms lasted until that evening (7/9/01).
intense pain; She can barely walk; eye sight has diminished; she has not driven or worked in over 17 months; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 30-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: GAIT DISTURBANCE (disability) with onset Apr2020, outcome "unknown", described as "She can barely walk"; VISUAL IMPAIRMENT (disability) with onset Apr2020, outcome "unknown", described as "eye sight has diminished"; PAIN (disability) with onset Apr2020, outcome "unknown", described as "intense pain"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (disability) with onset Apr2020, outcome "unknown", described as "she has not driven or worked in over 17 months". The patient underwent the following laboratory tests and procedures: Ophthalmological examination: Diminished, notes: Her eye sight has diminished.  Clinical course: Father of a female patient reported that, my 30 year old daughter is about 95% disabled. She is in intense pain, even on pain meds. She can barely walk and has seen dozens of specialist. None of the specialist have been helpful. This all started in Apr2020. This all started within hours of getting the 2 shot of the Pfizer vaccine. (2 shot protocol). She needs relief. Her eye sight has diminished and she has not driven or worked in over 17 months. Caller later stated that patient has no future.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions/allergies and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with GARDASIL 9 lot # M013636, expiration date: 15-FEB-2018, intramuscularly route per reporter (strength, dose and frequency were not reported) for prophylaxis, which was improperly stored at 32 and 36 Farenheit degrees for an unknown time. This excursion was detected due to a digital data logger, however no previous temperature excursion was reported.  No adverse effect was reported. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1701USA013133: US-009507513-1701USA013134: US-009507513-1701USA013139: US-009507513-1701USA013136: US-009507513-1701USA013137: US-009507513-1701USA010177: US-009507513-1701USA013132: US-009507513-1701USA013135.
This spontaneous case, was initially received on 03-Oct-2017, from other health professional and concerning a 29-year-old, adult, female patient. The patient's historical vaccine included unspecified influenza vaccine without any reaction. The patient's current condition included occasional reaction to egg, but did not react with an egg based vaccine in the past. The patient's concomitant medications were not reported. On 26-Sep-2017, the patient was administered with FLUCELVAX QIV (dose: 0.5 ml, batch number: 195126 (reported as 195106), expiry date: Apr-2018, route of administration, anatomical location: not reported). On an unspecified date, within 24 hours of vaccination, the patient had experienced symptoms of localized redness, swelling and heat at the site, which were lasted for 2 to 3 days. The events were lasted for 3 days and the patient was recovered from the events. The reporter assessed this case as non-serious. Non-significant case correction received with IRD 03-Oct-2017: Batch no. (195126) was captured in the case form and the narrative was amended accordingly.
A physician reported the occurrence of chest pain in a 62 year old male who was vaccinated with hep B vaccine recombinant for prophylaxis. The subject's relevant medical history included polycystic kidney disease treated with hemodialysis. Concurrent medications were unknown. In March 2001, April 2001, May 2001 and 8/31/01, the subject received injections of Engerix B. On 9/1/01, he experienced chest pain, a feeling of fullness in neck, and pain on swallowing. He was seen in the ER. X-rays of the neck and CT showed "lymphadenopathy in the neck area only." At that time, he had no indication of viral infection. Complete blood count revealed lymphopenia with a normal white blood cell count. On 11/8/01, it was determined that the subject had not seroconverted as a result of receiving Engerix B. CT performed on 11/9/01 indicated "no lymphadenopathy." The chest pain, feeling of fullness, and painful swallowing resolved on an unspecified date. The subject felt that the events were due to Engerix B administration. The reporting physician considered the events to be possibly related to Engerix B administration. The subject refused additional Engerix B booster as indicated for hemodialysis patients.
Immediate pain in left arm, which was unusual. Within an hour, stiffness and pain increased. When removing band-aid that evening, noticed that the actual injection site was above band-aid placement. The injection site was higher on left arm/closer to shoulder area than usual. Pain and stiffness was at highest within the weeks following vaccine. 2 months after vaccine, still experiencing pain, stiffness, reduced movement in left arm. Pain is experienced in upper arm and sometimes elbow area. Still very uncomfortable 2 months post vaccine. Will be seeking medical treatment.
On 3/22/01, post vax, had a small knot at injection site. On 3/23/2001 AM, had red, swollen, hard area, warm to touch about 10cm X 5.5CM on left upper thigh area. Ice pack to area and Benadryl every 6 hours.
FEVER 103 F; BODY ACHES; HEADACHE; This spontaneous report received from a consumer concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown, expiry: UNKNOWN) 0.5 ml, 1 total, administered on 05-MAR-2021 13:30 to Left Arm for prophylactic vaccination. No concomitant medications were reported.  On 05-MAR-2021, the subject experienced fever 103 f, body aches and headache. Laboratory data included: Body temperature (NR: not provided) 103 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from fever 103 f, and had not recovered from body aches, and headache. This report was non-serious.
I have a lot of inflammation and soreness in my knees and elbows all day long.  I've never dealt with this before.  I have had no treatment for this.
pt recv vax 8FEB99 9:50AM & AM awoke w/fever of 104 @ 2AM on 9FEB99;also had very sore arm, w/swelling on lt arm;T100.0 on 10FEB99;given APAP & Ibuprofen for fever;cool pack to arm;
fever, teeth chattering chills, exhaustion, slept for 24 hours, vomiting.
Adverse Event PT received 2nd dose of Pfizer at 1604, presented with pallor and decreased responsiveness at 1608. PT was sitting slumped in chair, supported by staff. PT was assisted to elevate feet. Aid was called at 1608 and arrived at 1609. PT was assisted to floor and reported feeling ?much better? on floor. VS were taken at 1610 (BP laying 70/40, HR 50, SPO2 98% on RA, BP at 1612 80/P). PT denies medical history, allergies, routine medication use, or previous vaccine/injection reaction. PT stated that she had ?too much anxiety? before vaccine and had begun to feel dizzy, PT was unsure if she completely lost awareness of surroundings during initial event. Pt also reports that she had just woken up and had not eaten or taken in any fluids before her vaccine appointment. PT was prompted to sit up at 1614 and did so without difficulty or requiring offered assistance, juice was provided. PT?s color was improved and PT said ?Now I?m much better.? At 1615, PT was assisted to chair (again, without difficulty) and VS were taken. BP was 78/42 sitting, HR was 67, SPO2 was 99%. VS at 1620 were 72/38 sitting, 72 HR. PT was responsive, responding to questions appropriately. PT reported that she did not know her baseline BP. At 1623, PT was assisted to stand (educated beforehand to sit in chair if she felt dizzy). PT denied dizziness, BP was 60/42 standing, HR 75. PT assisted back to chair, provided and consumed water, and ate a snack that she had brought along with her. PT was educated on safety/danger of falls, hypotension, and advised that a trip to the ER was recommended. PT verbalized understanding, but reported that she wished to wait a little longer at this time. BP at 1628 sitting was 72/44 and at 1637 BP was 70/40 sitting. CBG at 1652 was 163. BP at 1656 was 78/44 sitting. PT was again encouraged to take ambulance to ER and educated on hypotension and safety. PT verbalized understanding, declined ambulance transfer, and signed AMA paperwork. PT was advised to go to ER and educated on what to report to ER staff when she presented for services. At 1659, PT was assisted to wheelchair and exited facility in the presence of family in private vehicle.   Treatment: Assessment and treatment by EMTS, CBG taken  Outcome: PT exited facility in wheelchair, accompanied by family. Education provided, declined ambulance. Advised to present to ER for further TX, verbalized understanding.   HCP Responding:
pt received vaccine 9/17, came in pharmacy 9/23 to show bruised right arm (as result of immunization per patient). pt claimes day after immnuization (9/18) arm was sore and bruised, and has not resolved as of 9/23. c/o soreness, pain, no numbness,tingling, or "frozen" feeling.
First dose: The day after receiving the first dose experiencing these lumps down the front of the arm; The lumps going down it and they are tender; This is a spontaneous report from a contactable consumer (patient). An 84-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection) via an unspecified route, administered in left arm on 30Apr2021 as single dose for Covid-19 immunisation. The patient's medical history included ongoing atrial fibrillation (Afib) which was diagnosed five years ago and memory problems. No prior vaccinations (within 4 weeks). Concomitant medications were not reported. The day after receiving the first dose experiencing these lumps down the front of the arm on 01May2021. The lumps are all of them, all the way down the arm. The lumps are very tender, touchy and haven't gone away in 2021. It was the left arm after the first dose. The outcome of events was not recovered.  Information on the lot/batch number has been requested
About 7 cm symmetric pink minimally warm non tender minimally indurated pruritic pink circle at post injection region L thigh
Pt reaction to vaccine 5 min of administration, emesis and diaphoretic, pale, warm to touch. Pt stable with BP- 101/68, p=70, hr=56, r=20, pt also reported they did not eat today. Monitored for 15min to ensure pt safety and continued stability. Pt safe to discharge
Sore arm with mild or moderate pain, redness and at shot site. I also feel tired, and have muscle pain, headache, shivering, fever (not sure), stomach jitters, loss of appetite. Generally out of sorts, fluish, limiting my usual activities still 24 hours later.   I didn't have a reaction like this to the first vaccination -- or ever before to any vaccination -- only this 2nd shot.  Ibuprofen helps.
Retaining fluid; Affecting my legs/circulation in legs; Fatigued; Less than 35 days since first dose; Losing hair; Still fatigued with no energy; Lost my taste; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (Losing hair), AGEUSIA (Lost my taste), FLUID RETENTION (Retaining fluid), POOR PERIPHERAL CIRCULATION (Affecting my legs/circulation in legs) and ASTHENIA (Still fatigued with no energy  ) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047B21A and 031L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included PARACETAMOL (TYLENOL) for Arthritic-like pain, LOSARTAN for an unknown indication.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In April 2021, the patient experienced AGEUSIA (Lost my taste). In May 2021, the patient experienced ASTHENIA (Still fatigued with no energy  ). In July 2021, the patient experienced ALOPECIA (Losing hair). On an unknown date, the patient experienced FLUID RETENTION (Retaining fluid), POOR PERIPHERAL CIRCULATION (Affecting my legs/circulation in legs), FATIGUE (Fatigued) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Less than 35 days since first dose). The patient was treated with HYDROCHLOROTHIAZIDE on 14-Jul-2021 for Adverse event, at a dose of UNK, one time dose. At the time of the report, ALOPECIA (Losing hair), AGEUSIA (Lost my taste), FLUID RETENTION (Retaining fluid), POOR PERIPHERAL CIRCULATION (Affecting my legs/circulation in legs) and ASTHENIA (Still fatigued with no energy  ) outcome was unknown, FATIGUE (Fatigued) had not resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Less than 35 days since first dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Reporter stated he did not experienced any adverse events after first dose of Moderna vaccine which was done on 12-MAR-2021  On 03-SEP-2021 patient had undergone some bloodwork which results were not yet disclosed.  On 14-SEP-2021 his primary care provider ordered for ultrasound of legs.  Reporter also mentioned that after taking Hydrochlorothiazide 12.5mg/1day but it did not work.
Information has been received from a physician, via a company representative, concerning a patient (age and gender not reported) who on an unspecified date was vaccinated with a dose of PedvaxHIB (lot # not reported, though indicated "one of the recalls lot"). Subsequently the patient developed an injection site reaction (details not provided). The patient sought unspecified medical attention. At the time of this report, the patient was recovering from the event. Additional information has been requested.
Developed large itchy rash on left arm injection site on January 23.  Thought it was bad reaction to an insect bite until internet search revealed it was common side effect to Moderna vaccine.  Treated with OTC Cortisone lotion to relieve itch.  Itch still partially present but rash has disappeared as of 1/25